Novartis Plans Major Investment In All Drug Making Aspects In China
This article was originally published in PharmAsia News
Executive Summary
Swiss drug maker Novartis plans a major investment in China covering all aspects of selling pharmaceuticals in the country. Part of the planned investment includes greater emphasis on recruiting staff as its Chinese facilities expand, in part to launch six new drugs and conduct clinical trials this year. The CEO of Novartis Pharmaceuticals Division, Joseph Jimenez, said the company was continuing to put more money into its research and development center in Shanghai. Jimenez declined to set a figure on the investment, but said it would be considerable. (Click here for more